Xenon Pharmaceuticals Inc (XENE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.98B
Last updated: Nov 17, 2026 at 11:06 AM ET
Xenon Pharmaceuticals Inc (XENE) Competitors
The companies most similar to Xenon Pharmaceuticals are Xencor (XNCR), MBX Biosciences, Inc. Common Stock (MBX) and Telix Pharmaceuticals (TLX). By market cap, Xenon Pharmaceuticals ranks 2nd of the 13 companies on this page; Axsome Therapeutics (AXSM) is the largest at $7.45B.
Peer Comparison
XENE's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals (XENE) | $3.98B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Xencor Inc (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| MBX Biosciences, Inc. Common Stock (MBX) | $2.78B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $3.14B | N/A | 5.3x | 3.8% | -0.7% | 22.3% | 0.00% |
| Axsome Therapeutics Inc (AXSM) | $7.45B | N/A | 8.6x | -18.2% | -48.1% | 51.9% | 0.00% |
| Denali Therapeutics Inc (DNLI) | $3.00B | N/A | 159.3x | 0.0% | N/A | -100.0% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Dyne Therapeutics Inc (DYN) | $3.22B | N/A | N/A | 0.0% | -42.9% | 0.0% | 0.00% |
| Viking Therapeutics Inc (VKTX) | $3.73B | N/A | N/A | 0.0% | -61.0% | 0.0% | 0.00% |
| Viridian Therapeutics Inc (VRDN) | $3.51B | N/A | 128.5x | 0.0% | -41.8% | -63.5% | 0.00% |
| Pharvaris BV (PHVS) | $2.36B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Peer median | $3.07B | 266.5x | 14.2x | 0.0% | -42.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Xenon Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Xencor Inc (XNCR) | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed... | XNCR competitors |
| MBX Biosciences, Inc. Common Stock (MBX) | MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment... | MBX competitors |
| Telix Pharmaceuticals Limited (TLX) | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic... | |
| Axsome Therapeutics Inc (AXSM) | Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United... | AXSM competitors |
| Denali Therapeutics Inc (DNLI) | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. | DNLI competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
| Dyne Therapeutics Inc (DYN) | Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases... | DYN competitors |
| Viking Therapeutics Inc (VKTX) | Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. | VKTX competitors |
| Viridian Therapeutics Inc (VRDN) | Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. | VRDN competitors |
| Pharvaris BV (PHVS) | Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. | PHVS competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
Frequently Asked Questions About XENE
Who are Xenon Pharmaceuticals' main competitors?
The companies most similar to Xenon Pharmaceuticals include Xencor (XNCR), MBX Biosciences, Inc. Common Stock (MBX), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM) and Denali Therapeutics (DNLI), listed from the closest match.
Who is Xenon Pharmaceuticals' biggest competitor?
Axsome Therapeutics (AXSM) is the largest of the similar companies at $7.45B; Xencor (XNCR) is the closest match by business profile, size, sector and industry.
How does XENE stock compare with its competitors?
XENE's net margin is 0.0% against a peer median of 0.0%.
Which of Xenon Pharmaceuticals' competitors pays a higher dividend?
Xenon Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Xenon Pharmaceuticals bigger than its competitors?
No. Xenon Pharmaceuticals is 2nd by market cap among the 13 companies on this page; the largest is Axsome Therapeutics (AXSM) at $7.45B.
XENE pages: Overview, Earnings, Forecast, Financials, Competitors